Headlines about Baxter International (NYSE:BAX) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Baxter International earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 46.9935050371907 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- $2.74 Billion in Sales Expected for Baxter International Inc. (BAX) This Quarter (americanbankingnews.com)
- Baxter International Inc. Profit Rises 14% In Q3 – Markets Insider (markets.businessinsider.com)
- UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria (businessinsider.com)
- Baxter International (BAX) vs. CONMED Corporation (CNMD) Critical Survey (americanbankingnews.com)
- William Blair Equities Analysts Reduce Earnings Estimates for Baxter International Inc. (BAX) (americanbankingnews.com)
A number of equities research analysts have recently weighed in on BAX shares. BidaskClub lowered Baxter International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Cantor Fitzgerald set a $70.00 target price on Baxter International and gave the company a “buy” rating in a research note on Wednesday, July 26th. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $69.00 target price for the company in a research note on Tuesday, October 10th. BMO Capital Markets reissued a “buy” rating and issued a $70.00 target price on shares of Baxter International in a research note on Friday, October 13th. Finally, Morgan Stanley boosted their target price on Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research note on Thursday. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $67.00.
Baxter International (NYSE BAX) opened at 65.68 on Monday. The firm’s 50-day moving average price is $63.44 and its 200-day moving average price is $60.15. Baxter International has a 52-week low of $43.13 and a 52-week high of $65.70. The company has a market cap of $35.79 billion, a price-to-earnings ratio of 39.85 and a beta of 0.65.
Baxter International (NYSE:BAX) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.05. Baxter International had a net margin of 9.88% and a return on equity of 15.32%. The firm had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the previous year, the firm posted $0.56 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. On average, equities analysts anticipate that Baxter International will post $2.41 EPS for the current year.
In other news, Director Thomas T. Stallkamp sold 8,920 shares of Baxter International stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $62.28, for a total transaction of $555,537.60. Following the completion of the sale, the director now owns 16,263 shares of the company’s stock, valued at $1,012,859.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carole J. Shapazian sold 4,020 shares of Baxter International stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.61, for a total transaction of $247,672.20. Following the sale, the director now directly owns 13,868 shares of the company’s stock, valued at approximately $854,407.48. The disclosure for this sale can be found here. Insiders have sold 35,050 shares of company stock valued at $2,158,587 in the last ninety days. Insiders own 0.05% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2017/10/30/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-baxter-international-bax-stock-price.html.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
What are top analysts saying about Baxter International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Baxter International Inc. and related companies.